ACTIVE

PanTera

Financial year 2025 · closed on 31/12/2025
Net result
-3,9 M €
+54.7% YoY
Revenue
13,3 M €
+731.4% YoY
Equity
108,8 M €
+34.4% YoY
Workforce
24,2 ETP
+132.7% YoY

What does PanTera do?

PanTera is a Public limited company incorporated in 2022. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Mol. It employs on average 24,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0784.992.591
Incorporation
20/04/2022
Legal form
Public limited company
Registered office
Boeretang 192
2400 Mol · FlandreSee on map
Contributed capital
122 452 299,58 €
Latest accounts
31/12/2025
Average workforce
24,2 ETP
Joint committees (1)
  • 207
Signals
Solid equityLow riskGood liquidityHealthy social debtsHigh revenue
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 3 financial years

202520242023
Income statement
Revenue13,3 M €1,6 M €38,4 k €
EBITDA-1,6 M €-3,8 M €-752,5 k €
Operating result-3,6 M €-5,1 M €-1,1 M €
Net result-3,9 M €-8,6 M €-1,1 M €
Balance sheet
Equity108,8 M €81,0 M €40,2 M €
Total assets115,8 M €85,9 M €44,4 M €
Cash34,1 M €24,5 M €1,1 M €
Debts6,5 M €5,0 M €4,1 M €
Other
Workforce24,2 ETP10,4 ETP6,0 ETP
Estimate

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 9 active · 7 ended

Active mandates

Catherine Vandenborre

Director · since 24 novembre 2025 · until 10 septembre 2030

Active
Thomas Pevenage

Director · since 20 mars 2025 · until 24 novembre 2025

Active
Henri de Romrée de Vichenet

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Jean-François Rivassou

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Karen Verwimp

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Martijn Kleijwegt

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Pascal De Langhe

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
PRIMIX BIO VENTURES

Director · since 10 septembre 2024 · until 10 septembre 2030 · 0476.755.691

Represented by Luc DOCHEZ

Active
Soumya Chandramouli

Director · since 10 septembre 2024 · until 20 mars 2025

Active

Ended mandates

Thomas Pevenage

Director · since 20 mars 2025 · until 10 septembre 2030

Ended
Henri de Romrée

Director · since 25 avril 2024 · until 05 juin 2031

Ended
Cristiana Gameiro-Paris

Director · since 16 novembre 2023 · until 06 juin 2030

Ended
Karen Verwimp

Director · since 16 novembre 2023 · until 06 juin 2030

Ended
Annual accounts

Full financial information

202520242023
Type of accountFull modelFull modelFull model
Start of the financial year01/01/202501/01/202420/04/2022
Closing of the financial year31/12/202531/12/202431/12/2023
Length of the financial year12 months12 months21 months
Filing date08/09/202620/06/202523/07/2024
General meeting04/06/202630/04/202528/06/2024
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

4 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Full modelCorrection31/12/202504/06/202608/09/2026DutchPDF
Full model31/12/202504/06/202601/07/2026DutchPDF
Full model31/12/202430/04/202520/06/2025DutchPDF
Full model31/12/202328/06/202423/07/2024DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 9 active · 7 ended

Active mandates

Catherine Vandenborre

Director · since 24 novembre 2025 · until 10 septembre 2030

Active
Thomas Pevenage

Director · since 20 mars 2025 · until 24 novembre 2025

Active
Henri de Romrée de Vichenet

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Jean-François Rivassou

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Karen Verwimp

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Martijn Kleijwegt

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
Pascal De Langhe

Director · since 10 septembre 2024 · until 10 septembre 2030

Active
PRIMIX BIO VENTURES

Director · since 10 septembre 2024 · until 10 septembre 2030 · 0476.755.691

Represented by Luc DOCHEZ

Active
Soumya Chandramouli

Director · since 10 septembre 2024 · until 20 mars 2025

Active

Ended mandates

Thomas Pevenage

Director · since 20 mars 2025 · until 10 septembre 2030

Ended
Henri de Romrée

Director · since 25 avril 2024 · until 05 juin 2031

Ended
Cristiana Gameiro-Paris

Director · since 16 novembre 2023 · until 06 juin 2030

Ended
Karen Verwimp

Director · since 16 novembre 2023 · until 06 juin 2030

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Registered office27/05/2026
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Capital / shares26/08/2025
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN
    PDF
  • Capital / shares19/12/2024
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN
    PDF
  • Mandates20/09/2024
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates08/08/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares05/04/2024
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN
    PDF
  • Mandates18/12/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates27/11/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025-3,9 M €
  2. 13/08/2025
    augmentation_capital
  3. 2024
    Annual accounts 2024-8,6 M €
  4. 06/12/2024
    augmentation_capital
  5. 10/09/2024
    augmentation_capital
  6. 10/09/2024
    augmentation_capital
  7. 10/09/2024
    augmentation_capital
  8. 01/07/2024
    nominationSven Van den Berghe — persoon belast met het dagelijks bestuur
  9. 21/03/2024
    apport
  10. 21/03/2024
    augmentation_capital
  11. 21/03/2024
    autre
  12. 16/01/2024
    nominationRomain Seffer — commissaris
  13. 2023
    Annual accounts 2023-1,1 M €
  14. 16/11/2023
    nominationLEGRAIN Olivier Jacques Ghislain — bestuurder
  15. 16/11/2023
    nominationGAMEIRO-PARIS Cristiana — bestuurder
  16. 16/11/2023
    nominationVERWIMP Karen Magdalena Frans — bestuurder
  17. 01/06/2022
    nominationSven Van den Berghe — CEO
  18. 20/04/2022
    IncorporationPublic limited company
  19. 19/04/2022
    nominationCHANDRAMOULI Soumya — bestuurder
  20. 19/04/2022
    nominationSCUTNAIRE Bruno — bestuurder
  21. 19/04/2022
    nominationBAETEN Peter Hendrik — bestuurder
  22. 19/04/2022
    nominationDE LANGHE Pascal — bestuurder
  23. 19/04/2022
    apportSTUDIECENTRUM VOOR KERNENERGIE - CENTRE D'ETUDE DE L'ENERGIE NUCLÉAIRE
  24. 19/04/2022
    apportION BEAM APPLICATIONS
  25. 19/04/2022
    constitutionSTUDIECENTRUM VOOR KERNENERGIE - CENTRE D'ETUDE DE L'ENERGIE NUCLÉAIRE — founder
  26. 19/04/2022
    constitutionION BEAM APPLICATIONS — founder